Neuronetics Announces Positive Real-World Findings on NeuroStar TMS for Treating Depression in Adolescents and Young Adults

Neuronetics announces positive real-world findings on NeuroStar TMS treatment for adolescents with depression, published in JAACAP Open.

Quiver AI Summary

Neuronetics, Inc. announced significant findings regarding the effectiveness of its NeuroStar TMS (transcranial magnetic stimulation) treatment for major depressive disorder in adolescents and young adults, published in the Journal of the American Academy of Child & Adolescent Psychiatry Open. The study showed that approximately 70% of the 1,283 patients, including those aged 12-21, reported clinically meaningful improvements in their depressive symptoms, similar to outcomes seen in adult populations. Following FDA clearance for treating adolescents in March 2024, there has been a notable increase in the number of young patients receiving this treatment. Neuronetics emphasizes the urgent need for effective treatment options for adolescents, as many remain untreated despite the prevalence of depression in this age group. The company is committed to expanding access to NeuroStar TMS and improving mental health outcomes for these patients.

Potential Positives

Neuronetics has published significant findings in a leading medical journal, supporting the efficacy of NeuroStar TMS for treating depression in adolescents and young adults.
The study shows that approximately 70% of the patients reported meaningful improvement, reinforcing the treatment's effectiveness.
NeuroStar TMS is positioned as a vital treatment option for adolescents with major depressive disorder, addressing a critical health need in a largely untreated population.
The continued growth in the number of adolescents treated with NeuroStar demonstrates the treatment's rapid acceptance and increasing market share in the pediatric mental health sector.

Potential Negatives

Despite the positive findings presented, the press release does not address any potential side effects or risks associated with the NeuroStar TMS treatment, which could be a concern for patients and healthcare providers.
The lack of specific comparisons with competitor treatments or detailed information about the market position of NeuroStar TMS may suggest vulnerabilities in its competitive advantage.
The press release emphasizes that only two medications are FDA-approved for treating adolescent major depressive disorder, thereby highlighting a limited treatment landscape that may increase scrutiny on the efficacy and safety of NeuroStar TMS as an alternative option.

FAQ

What are the latest findings about NeuroStar TMS for adolescents?

The latest study shows strong antidepressant effects of NeuroStar TMS in adolescents and young adults, consistent with adult results.

How does NeuroStar TMS compare to traditional medications for depression?

NeuroStar TMS offers a non-drug, noninvasive alternative, providing significant safety and effectiveness for treating major depressive disorder.

What is the significance of the NeuroStar TrakStar Clinical Database?

The NeuroStar TrakStar Clinical Database is the world's largest database of depression outcomes, supporting the efficacy of NeuroStar TMS treatments.

What was the patient sample size in the NeuroStar TMS study?

The study included 1,283 patients, with 682 aged 12-19 and 601 aged 20-21, showcasing robust clinical improvements.

Who should consider NeuroStar TMS treatment?

Adolescents and young adults aged 15-21 with major depressive disorder may benefit from NeuroStar TMS, especially when traditional treatments fail.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$STIM Insider Trading Activity

$STIM insiders have traded $STIM stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.

Here’s a breakdown of recent trading of $STIM stock by insiders over the last 6 months:

STEPHEN FURLONG (EVP, CFO and Treasurer) has made 0 purchases and 6 sales selling 244,855 shares for an estimated $1,022,974.
KEITH J SULLIVAN (President and CEO) has made 0 purchases and 3 sales selling 91,366 shares for an estimated $363,690.
WILLIAM ANDREW MACAN (EVP, GC, CCO and CS) has made 0 purchases and 4 sales selling 33,487 shares for an estimated $132,726.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$STIM Hedge Fund Activity

We have seen 68 institutional investors add shares of $STIM stock to their portfolio, and 19 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

IKARIAN CAPITAL, LLC added 1,100,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,048,000
VANGUARD GROUP INC added 1,024,680 shares (+80.0%) to their portfolio in Q1 2025, for an estimated $3,770,822
MANATUCK HILL PARTNERS, LLC added 920,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $3,385,600
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 761,911 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,803,832
MILLENNIUM MANAGEMENT LLC added 657,725 shares (+inf%) to their portfolio in Q1 2025, for an estimated $2,420,428
GOLDMAN SACHS GROUP INC added 610,014 shares (+2993.3%) to their portfolio in Q1 2025, for an estimated $2,244,851
MASTERS CAPITAL MANAGEMENT LLC removed 500,000 shares (-33.3%) from their portfolio in Q1 2025, for an estimated $1,840,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$STIM Analyst Ratings

Wall Street analysts have issued reports on $STIM in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Canaccord Genuity issued a "Buy" rating on 03/05/2025
Citizens Capital Markets issued a "Market Outperform" rating on 03/05/2025

To track analyst ratings and price targets for $STIM, check out Quiver Quantitative's $STIM forecast page.

$STIM Price Targets

Multiple analysts have issued price targets for $STIM recently. We have seen 2 analysts offer price targets for $STIM in the last 6 months, with a median target of $7.5.

Here are some recent targets:

William Plovanic from Canaccord Genuity set a target price of $8.0 on 03/05/2025
Daniel Stauder from Citizens Capital Markets set a target price of $7.0 on 03/05/2025

Full Release

MALVERN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the publication of significant real-world findings in the Journal of the American Academy of Child & Adolescent Psychiatry Open (JAACAP Open), a leading peer-reviewed medical journal covering pediatric psychiatry. The study found strong antidepressant treatment effects in adolescent and young adult patients treated with NeuroStar TMS (transcranial magnetic stimulation). The results in these adolescent and young adult patients were consistent with those previously reported in adults. ¹

“Since NeuroStar was the first TMS manufacturer to receive FDA clearance as an add-on therapy to treat adolescents, ages 15-21, with major depressive disorder in March 2024, we have seen over a one-third increase in adolescents being treated with NeuroStar, highlighting the importance and rapid uptake in the younger patient population, ² ” said Keith J. Sullivan, President and CEO of Neuronetics. “These findings reinforce the unique leadership role Neuronetics plays both as an innovator and a resource for clinical research with our proprietary TrakStar ^® dataset. We will continue to work with providers and payers to expand access to NeuroStar TMS for appropriate young patients.”

The findings are based on research from the NeuroStar TrakStar Clinical Database, the world's largest database of depression outcomes. In a sample of 1,283 patients comprised of 682 patients aged 12-19 and 601 patients aged 20-21, approximately 70% of patients reported positive clinically meaningful improvement, and less than one percent reported clinically meaningful worsening, as measured by the Patient Health Questionnaire-9 (PHQ-9). The trajectory of improvement was similar to results from the adult populations, which showed a robust correlation between the sessions completed and the clinical improvement in depression symptoms, reaffirming the importance of completing a full treatment course to maximize treatment benefits. ¹

“These data, derived from the largest sample of adolescent and young adult patients who have received NeuroStar TMS, demonstrate the undeniable results NeuroStar TMS provides, which is consistent with the efficacy and meaningful benefit we see with adult populations,” said Todd M. Hutton, MD, Chief Medical Officer of Southern California TMS Center and former President of the Clinical TMS Society. “One in five adolescents experience an episode of major depressive disorder, and the majority go untreated as there are only two FDA-approved medications for this population and both come with major safety warnings. ^3,4,5 There is a huge opportunity for NeuroStar TMS to provide a safe and effective option to these patients at a critical time in their lives and development.”

For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO ^® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant. ¹ Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com .

Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
[email protected]

Media:
EvolveMKD
646.517.4220
[email protected]

References:

Croarkin PE, Aaronson ST, Carpenter LL, Hutton TM, Pages K, Chen B, Sackeim HA. The Effectiveness of Transcranial Magnetic Stimulation in Adolescents and Young Adults With Major Depressive Disorder. JAACAP Open (2025), doi: 10.1016/j.jaacop.2025.06.006.
FDA 510(k) Clearance K231926. Data on File. Neuronetics. 2025.
National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/major-depression#part_2565 .
Wilson, S. Dumornay, N.M. Rising Rates of Adolescent Depression in the United States: Challenges and Opportunities in the 2020s. J Adolesc Health. Mar 2022; 70:354-355.
Flores, M.W., Sharp, A., Carson, N.J. et al. Estimates of Major Depressive Disorder and Treatment Among Adolescents by Race and Ethnicity. JAMA Pediatrics. 2023; 177:1215-1223.

____________________________
¹ The effectiveness of SPRAVATO ^® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO ^® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO ^® . For more important safety information about SPRAVATO ^® , please visit spravatohcp.com.